John C.M. Farquhar, chief executive of HeartFlow Inc., sold 27,230 shares of common stock on August 21 for a total of $1.36 million, according to a regulatory filing.
The disposal was executed at $50.00 per share under a Rule 10b5-1 trading plan adopted by Farquhar on September 12, 2025. Following the transaction, he retains direct ownership of 360,814 shares of the company’s common stock.
HeartFlow’s stock has gained 117% over the past six months and was trading near its 52-week high of $51.19 at the time of the sale. InvestingPro analysis had ranked the shares among the most overvalued based on fair-value metrics.
The company reported adjusted earnings per share of negative $0.07 for the second quarter of 2026, narrower than the expected loss of $0.19 and beating the Street estimate. Revenue rose 48% year-over-year to $64.1 million, exceeding both Stifel’s projection of $56.7 million and the consensus estimate of $56.6 million.
Analysts at Stifel raised the price target on HeartFlow shares to $45 from $40 while maintaining a Buy rating, citing strong demand for coronary artery disease diagnostics and progress in the plaque and FFRCT businesses.
